{
  "docId": "019de071-1981-7442-94ed-ee285d10f59b",
  "docSlug": "c18efbd116f640ca1060cd96d0c18250",
  "documentTitle": "Alkermes | Results Presentation Deck | 31 slides",
  "authorId": "alkermes",
  "authorName": "Alkermes",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 25,
  "pageCount": 31,
  "prevPage": 24,
  "nextPage": 26,
  "slideType": "key_takeaways",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 3,
  "notes": "Data cut off March 19, 2021. Serum concentrations after the first dose of SC nemvaleukin.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-1981-7442-94ed-ee285d10f59b/25",
  "deckHref": "/decks/019de071-1981-7442-94ed-ee285d10f59b",
  "deckJsonHref": "/decks/019de071-1981-7442-94ed-ee285d10f59b.json",
  "deckAnchorHref": "/decks/019de071-1981-7442-94ed-ee285d10f59b#slide-25",
  "components": [
    {
      "bbox": {
        "h": 0.5,
        "w": 0.2,
        "x": 0.62,
        "y": 0.25
      },
      "kind": "chart",
      "text": "IL-6 levels over time",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "13b87ae8-52d7-4d34-9b72-16a7f02c804c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.2,
        "x": 0.18,
        "y": 0.25
      },
      "kind": "chart",
      "text": "Nemvaleukin concentration over time",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "52f6ccbf-d743-4c75-84ca-36b1cf13cb10",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.2,
        "x": 0.4,
        "y": 0.25
      },
      "kind": "chart",
      "text": "IFNy levels over time",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a8e7c785-0ec6-437c-addb-56e5d00fc9b9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.8
      },
      "kind": "paragraph",
      "text": "SC nemvaleukin showed dose-dependent increase in exposure and led to increased levels of IFNy, a cytokine for anti-tumor activity, with minimal transient increase in IL-6, which is associated with side effects of immunotherapy",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bd3883de-9d6e-4115-b0cb-172c8bf7bb8c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.9
      },
      "kind": "source-note",
      "text": "*Serum concentrations after the first dose of SC nemvaleukin. Data cut off March 19, 2021",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5a8d7efe-a9f2-45c1-81ea-2437f102091e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "SC Nemvaleukin Demonstrated Dose-Dependent Pharmacodynamic Response, Similar to IV Nemvaleukin",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "94f63dbb-1897-4683-9516-b6d59fd1e4ce",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Data Story Arc",
      "slug": "data-story-arc",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "e5c58f60-bc75-4f0e-91f5-c3964da92674",
      "evidence": "The slide uses charts to show the dose-dependent increase in exposure and the levels of IFNy and IL-6, creating a narrative around the data.",
      "confidence": 0.7
    },
    {
      "name": "Storytelling: audience calibration",
      "slug": "audience",
      "agent": "storyteller",
      "layer": "slide",
      "matchId": "47ba6ca4-5cb8-41a0-8f4e-547245ba1d9f",
      "evidence": "The slide presents data on the pharmacodynamic response of SC Nemvaleukin, indicating a focus on the target audience's interest in the drug's efficacy.",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 31,
      "from": 22,
      "beatId": "6729dbcf-9af8-4183-a612-b8bbf1c1b0a8",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Impact & Next Steps",
      "beatSlug": "consultants-gambit-impact-next-steps",
      "evidence": "The presentation concludes with a summary of results and a panel discussion",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}